Financial Performance Overview
WuXi AppTec, a leading global provider of R&D and manufacturing services for the pharmaceutical and life sciences industries, recently released its financial results for the first three quarters of 2024. Despite facing external challenges, the company reported a robust performance with significant revenue growth and profitability. Revenues in the third quarter reached over RMB 10 billion, representing a 14.6% increase year-over-year when excluding COVID-19 commercial projects.
Quarterly Revenue and Profit Highlights
The overall revenue for WuXi AppTec in the first three quarters of 2024 totaled RMB 27.7 billion, growing 4.6% year-over-year, excluding the impacts from COVID-19 related projects. This continuous improvement indicates the company’s resilience and adaptability in the rapidly changing healthcare landscape.
Revenue Growth Details
In the third quarter alone, the revenue was an impressive RMB 10.5 billion, showcasing a strong rebound compared to previous quarters. The company’s efforts to streamline operations and enhance service delivery have clearly paid off.
Net Profit Figures
Net profit attributable to the owners of the company reached RMB 6.5 billion, translating to a diluted earnings per share (EPS) of RMB 2.24. When adjusted for non-IFRS measures, the net profit was even higher, amounting to RMB 7.3 billion, corresponding to an adjusted EPS of RMB 2.52, reflecting strong operational efficiency.
Solid Operational Cash Flow
WuXi AppTec’s operating cash flow also saw an impressive increase of 10.4% year-over-year, signifying robust financial health. The free cash flow recorded for the first three quarters stood at RMB 5.56 billion, further solidifying the company's ability to fund growth initiatives.
Backlog and Customer Base Expansion
As of September 30, 2024, WuXi AppTec reported a backlog of RMB 43.82 billion, which marks a 35.2% increase compared to the previous year. The company maintained a strong clientele, adding over 800 new customers while retaining over 6,000 existing active clients.
Growth Drivers and Future Outlook
The continued demand across various regions has significantly contributed to the company’s strong performance. WuXi AppTec's unique fully integrated Contract Research, Development and Manufacturing Organization (CRDMO) platform is at the forefront of this growth. With a diverse portfolio, the company supports innovations in drug discovery and development.
Director's Statement
Dr. Ge Li, Chairman and CEO of WuXi AppTec, highlighted the company’s progress, stating, "Despite the challenges, we have successfully achieved sustained revenue and profit growth. Our total revenue has rebounded significantly, and we remain committed to serving our customers and innovating within the healthcare sector." He concluded by reassuring stakeholders about the company’s strategic path forward.
Segment Performance Analysis
The growth performance varied across WuXi's segments. Notably, the WuXi Chemistry segment experienced positive growth, achieving revenue of approximately RMB 7.88 billion in Q3 2024. Excluding COVID-19 related projects, the growth in this segment was 26.4% year-over-year.
Investment in Capabilities
WuXi AppTec continues to invest in its capabilities, including the expansion of its Solid Phase Peptide Synthesizer systems, which increased to 32,000L in January 2024, with expectations of reaching 41,000L in the upcoming years.
New Developments in Singapore
In May 2024, the company announced the groundbreaking of a new research and development facility in Singapore, scheduled to commence operations in 2027. This development symbolizes WuXi's commitment to expanding its global footprint and capabilities in biopharmaceutical manufacturing.
Frequently Asked Questions
What is the revenue growth percentage reported by WuXi AppTec in Q3 2024?
The revenue growth reported by WuXi AppTec in Q3 2024 was 14.6% year-over-year excluding COVID-19 commercial projects.
What was the net profit for WuXi AppTec in the first three quarters of 2024?
The net profit attributable to the owners of the company reached RMB 6.5 billion for the first three quarters of 2024.
How many new customers did WuXi AppTec add in 2024?
WuXi AppTec added over 800 new customers in the first three quarters of 2024, while maintaining a base of over 6,000 existing customers.
What is the company’s outlook on revenue for the year 2024?
WuXi AppTec expects to achieve revenue of RMB 38.3 - 40.5 billion for the year 2024.
What strategic initiatives has WuXi undertaken recently?
WuXi has recently invested in expanding its operational capabilities and announced the groundbreaking of a new R&D facility in Singapore, expected to enhance its biopharmaceutical services.
